Abstract
Purpose
To evaluate the efficacy and safety of topical 0.005% tacrolimus eye drop for treatment of refractory vernal keratoconjunctivitis (VKC).
Methods
This prospective study included 20 eyes of 10 patients with refractory VKC, who had active symptomatic disease despite conventional medications including topical steroids. After discontinuing all other medications, patients were treated with topical 0.005% tacrolimus eye drop four times a day. Changes in subjective symptoms and objective signs after treatment were evaluated, and development of possible complications was assessed.
Results
Mean age of patients was 21.3±7.4 years and mean duration of VKC was 12.1±5.8 years. After starting tacrolimus eye drop, patients were followed for a mean duration of 10.7±3.7 months (range, 6–15 months). All symptoms including itching, redness, photosensitivity, foreign body sensation, and mucus discharge improved after the treatment; itching was the first symptom to show dramatic relief. In addition, there was improvement in objective signs including conjunctival hyperaemia, conjunctival papillary hypertrophy, giant papillae, limbal hypertrophy, corneal punctate epithelial erosions, and corneal pannus; conjunctival hyperaemia was the first sign to show improvement. No patient required addition of other medications including steroids for further relief. Any attempt to discontinue tacrolimus eye drop was associated with recurrence of patients’ symptoms and signs, necessitating continued use of the medication during the entire follow-up time. No ocular complication related to tacrolimus was noted.
Conclusion
Topical 0.005% tacrolimus eye drop seemed to be a safe and effective treatment for steroid-resistant refractory VKC; however, long-term use was needed to control the disease.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Bielory L, Frohman LP . Allergic and immunologic disorders of the eye. J Allergy Clin Immunol 1992; 89 (1 Part 1): 1–15.
Bonini S, Bonini S, Lambiase A, Marchi S, Pasqualetti P, Zuccaro O et al. Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term follow-up. Ophthalmology 2000; 107 (6): 1157–1163.
Tabbara KF . Ocular complications of vernal keratoconjunctivitis. Can J Ophthalmol 1999; 34 (2): 88–92.
BenEzra D, Pe’er J, Brodsky M, Cohen E . Cyclosporine eye drops for the treatment of severe vernal keratoconjunctivitis. Am J Ophthalmol 1986; 101 (3): 278–282.
Secchi AG, Tognon MS, Leonardi A . Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am J Ophthalmol 1990; 110 (6): 641–645.
Bleik JH, Tabbara KF . Topical cyclosporine in vernal keratoconjunctivitis. Ophthalmology 1991; 98 (11): 1679–1684.
Sawada S, Suzuki G, Kawase Y, Takaku F . Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol 1987; 139 (6): 1797–1803.
Kobayashi C, Kanai A, Nakajima A, Okumura K . Suppression of corneal graft rejection in rabbits by a new immunosuppressive agent, FK-506. Transplant Proc 1989; 21 (1 Part 3): 3156–3158.
Nishi M, Herbort CP, Matsubara M, Morishita M, Nishimura M, Nieda M et al. Effects of the immunosuppressant FK506 on a penetrating keratoplasty rejection model in the rat. Invest Ophthalmol Vis Sci 1993; 34 (8): 2477–2486.
Sloper CM, Powell RJ, Dua HS . Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmology 2001; 108 (10): 1838–1844.
Chen J, Zhou Q, Zeng J, Xu JT, Zhao SB, Wang YP . The study of FK506 eye drops preventing and treating immune rejection on limbal allograft transplantation. Zhonghua Yan Ke Za Zhi 2003; 39 (9): 550–554 (in Chinese).
Yalçindag FN, Incel O, Ozdemir O . Effectiveness of tacrolimus in high-risk limbal allo-graft transplantation. Ann Ophthalmol (Skokie) 2008; 40 (3–4): 152–156.
Kawashima H, Fujino Y, Mochizuki M . Effects of a new immunosuppressive agent, FK506, on experimental autoimmune uveoretinitis in rats. Invest Ophthalmol Vis Sci 1988; 29 (8): 1265–1271.
Mochizuki M, Ikeda E, Shirao M, Fujito S, Yoshimura K, Shimada N . Preclinical and clinical study of FK506 in uveitis. Curr Eye Res 1992; 11 (Suppl): 87–95.
Sloper CM, Powell RJ, Dua HS . Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 1999; 106 (4): 723–728.
Iwamoto H, Yoshida H, Yoshida O, Fukushima A, Ueno H . Inhibitory effects of FK506 on the development of experimental allergic/immune-mediated blepharoconjunctivitis in Lewis rats by systemic but not by topical administration. Graefes Arch Clin Exp Ophthalmol 1999; 237 (5): 407–414.
Mayer K, Reinhard T, Reis A, Böhringer D, Sundmacher R . FK 506 ointment 0.1%—A new therapeutic option for atopic blepharitis. Clinical trial with 14 patients. Klin Monbl Augenheilkd 2001; 218 (11): 733–736. German.
Rikkers SM, Holland GN, Drayton GE, Michel FK, Torres MF, Takahashi S . Topical tacrolimus treatment of atopic eyelid disease. Am J Ophthalmol 2003; 135 (3): 297–302.
Virtanen HM, Reitamo S, Kari M, Kari O . Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study. Acta Ophthalmol Scand 2006; 84 (5): 693–695.
Zribi H, Descamps V, Hoang-Xuan T, Crickx B, Doan S . Dramatic improvement of atopic keratoconjunctivitis after topical treatment with tacrolimus ointment restricted to the eyelids. J Eur Acad Dermatol Venereol 2009; 23 (4): 489–490.
Kymionis GD, Goldman D, Ide T, Yoo SH . Tacrolimus ointment 0.03% in the eye for treatment of giant papillary conjunctivitis. Cornea 2008; 27 (2): 228–229.
Vichyanond P, Tantimongkolsuk C, Dumrongkigchaiporn P, Jirapongsananuruk O, Visitsunthorn N, Kosrirukvongs P . Vernal keratoconjunctivitis: result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment. J Allergy Clin Immunol 2004; 113 (2): 355–358.
Miyazaki D, Tominaga T, Kakimaru-Hasegawa A, Nagata Y, Hasegawa J, Inoue Y . Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology 2008; 115 (6): 988–992.e5.
Ohashi Y, Ebihara N, Fujishima H, Fukushima A, Kumagai N, Nakagawa Y et al. A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis. J Ocul Pharmacol Ther 2010; 26 (2): 165–174.
Stumpf T, Luqmani N, Sumich P, Cook S, Tole D . Systemic tacrolimus in the treatment of severe atopic keratoconjunctivitis. Cornea 2006; 25 (10): 1147–1149.
Anzaar F, Gallagher MJ, Bhat P, Arif M, Farooqui S, Foster CS . Use of systemic T-lymphocyte signal transduction inhibitors in the treatment of atopic keratoconjunctivitis. Cornea 2008; 27 (8): 884–888.
Nivenius E, van der Ploeg I, Jung K, Chryssanthou E, van Hage M, Montan PG . Tacrolimus ointment vssteroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis. Eye (Lond) 2007; 21 (7): 968–975.
Sengoku T, Sakuma S, Satoh S, Kishi S, Ogawa T, Ohkubo Y et al. Effects of FK506 eye drops on late and delayed-type responses in ocular allergy models. Clin Exp Allergy 2003; 33 (11): 1555–1560.
Joseph MA, Kaufman HE, Insler M . Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders. Cornea 2005; 24 (4): 417–420.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
This paper was presented at ASCRS Meeting, Boston, April 2010.
Rights and permissions
About this article
Cite this article
Kheirkhah, A., Zavareh, M., Farzbod, F. et al. Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis. Eye 25, 872–880 (2011). https://doi.org/10.1038/eye.2011.75
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2011.75
Keywords
This article is cited by
-
Applications of topical immunomodulators enhance clinical signs of vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC): a meta-analysis
International Ophthalmology (2024)
-
A comparative study between ciclosporine A eye drop (2%) and tacrolimus eye ointment (0.03%) in management of children with refractory vernal keratoconjunctivitis
Graefe's Archive for Clinical and Experimental Ophthalmology (2022)
-
Long-term results of topical 0.02% tacrolimus ointment for refractory ocular surface inflammation in pediatric patients
BMC Ophthalmology (2021)
-
Role of combined immunomodulator therapy in severe steroid intolerant vernal keratoconjunctivitis
Eye (2021)
-
Dermatologic tacrolimus ointment on the eyelids for steroid-refractory vernal keratoconjunctivitis
Graefe's Archive for Clinical and Experimental Ophthalmology (2019)
